Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study.

ABSTRACT:

Aims

The aim of the LAICA study was to evaluate the long-term effectiveness and safety of intermittent levosimendan infusion in patients with advanced heart failure (AdHF).

Methods and results

This was a multicentre, randomized, double-blind, placebo-controlled clinical trial of intermittent levosimendan 0.1 μg/kg/min as a continuous 24-h intravenous infusion administered once monthly for 1 year in patients with AdHF. The primary endpoint [incidence of rehospitalization (admission to the emergency department or hospital ward for >12 h) for acute decompensated HF or clinical deterioration of the underlying HF] occurred in 23/70 (33%) of the levosimendan group (Group I) and 12/27 (44%) of the placebo group (Group II) (P = 0.286). The incidence of hospital readmissions for acut

SUBMITTER: Garcia-Gonzalez MJ 

PROVIDER: S-EPMC8712777 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature